
    
      The primary purpose of this protocol is to make arbekacin available for treatment of patients
      with infections caused by multidrug-resistant organisms when treatment with other antibiotics
      cannot be used due to unavailability, intolerance, contraindications, or treatment
      non-response.
    
  